Ask AI
ProCE Banner Activity

Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities

Podcast Episodes

Listen to Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities.

Released: May 29, 2025

Expiration: November 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC., in partnership with Practicing Clinicians Exchange (PCE) and ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Partners

Practicing Clinicians Exchange, LLC

ProCE Banner

ProCE, LLC

ProCE Banner

Disclosure

Primary Author

La-Urshalar B. Brock, FNP-BC, CNM, PhD Candidate: consultant/advisor/speaker: AstraZeneca.

Jordan Hill, PharmD, BCOP, has no relevant financial relationships to disclose.

Sara A. Hurvitz, MD, FACP: researcher: Arvinas, AstraZeneca, Boehringer Ingelheim, Celcuity, Dantari, G1 Therapeutics, Genentech/Roche, Gilead, Greenwich LifeSciences, Immunomedics, Jazz/Zymeworks, Lilly, Loxo, Novartis, Orinove, Orum, Pfizer, Puma, Radius, Sanofi, Seagen, Stemline/Menarini; data and safety monitoring board: Atossa.